Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725634 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Malignant Solid Tumor, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT00725634 is a Phase 1 study of Multiple Myeloma and Malignant Solid Tumor that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 41 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00725634, a Phase 1 study of Multiple Myeloma and Malignant Solid Tumor, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the safety, tolerability and DLTs of AV-299 in combination with erlotinib in patients with relapsed or refractory solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL AV-299
- BIOLOGICAL AV-299 + erlotinib
Study Locations (3)
Arizona
- Investigational Site 2 - Scottsdale
Ohio
- Investigational Site 3 - Columbus
Texas
- Investigational Site 1 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725634
The ClinicalTrials.gov registry entry for NCT00725634 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which AV-299 is the first listed.
NCT00725634 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT00725634 about?
NCT00725634 is a clinical study titled "A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma". Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the safety, tolerability and DLTs...
What is the current status of trial NCT00725634?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2008-09. Estimated completion is 2013-12.
What conditions does trial NCT00725634 study?
This clinical trial studies the following conditions: Multiple Myeloma, Malignant Solid Tumor, Lymphomas.
What interventions are being tested in trial NCT00725634?
The interventions under investigation include: AV-299 (BIOLOGICAL), AV-299 + erlotinib (BIOLOGICAL).
Who is sponsoring clinical trial NCT00725634?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00725634 being conducted?
This trial has 3 study locations across Arizona, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.